Drug intelligence / Profile preview

Ad26.Mos4.HIV + CH505 TF chTrimer + ALFQ

Development stage: Unknown
Lead developer: U.S. Army Medical Research and Development Command
Modality: Recombinant Proteins and Enzymes, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Ad26.Mos4.HIV + CH505 TF chTrimer + ALFQ is an experimental HIV vaccine regimen designed to prevent HIV-1 infection. It is being developed by the U.S. Army Medical Research and Development Command (USAMRDC) in collaboration with Janssen Vaccines & Prevention B.V. and Duke University. The regimen utilizes a heterologous prime-boost strategy: Ad26.Mos4.HIV is a replication-incompetent adenovirus serotype 26 vector expressing mosaic HIV-1 antigens; CH505 TF chTrimer is a stabilized, soluble HIV-1 envelope (Env) protein trimer derived from a transmitted/founder virus; and ALFQ (Army Liposomal Formulation containing QS-21) is a potent adjuvant containing monophosphoryl lipid A (MPLA) and QS-21. The combination aims to induce both robust cellular immune responses and broadly neutralizing antibodies (bNAbs) against the HIV-1 envelope protein. It is currently being evaluated in the Phase I RV591 trial to compare standard versus rapid dose-escalating schedules.

Other names: Ad26.Mos4.HIV + CH505 TF chTrimer + ALFQ

Targets

gp41 (Human immunodeficiency virus type 1 glycoprotein 41)

Beyond the preview

Go deeper on Ad26.Mos4.HIV + CH505 TF chTrimer + ALFQ.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ad26.Mos4.HIV + CH505 TF chTrimer + ALFQ.

Explore the full profile